NO20072654L - Cancer behandling - Google Patents

Cancer behandling

Info

Publication number
NO20072654L
NO20072654L NO20072654A NO20072654A NO20072654L NO 20072654 L NO20072654 L NO 20072654L NO 20072654 A NO20072654 A NO 20072654A NO 20072654 A NO20072654 A NO 20072654A NO 20072654 L NO20072654 L NO 20072654L
Authority
NO
Norway
Prior art keywords
methods
cancer treatment
cancer cells
treatment
disaster
Prior art date
Application number
NO20072654A
Other languages
English (en)
Inventor
Helene Heather Bendall
Gary T Elliott
Lorenzo M Leoni
Carol Christina Niemeyer
Pratik S Multani
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072654(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20072654L publication Critical patent/NO20072654L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Metoder og preparater for behandling av kreft karakterisert ved dødsresistente kreftceller er beskrevet. Generelt involverer slike metoder administrering av en terapeutisk effektiv mengde av en forbindelse som fremkaller mitotisk katastrofe i noen og fortrinnsvis de fleste eller alle kreftcellene. Metoder for bedømmelse av effektiviteten av slike behandlinger er også gitt.
NO20072654A 2004-11-05 2007-05-24 Cancer behandling NO20072654L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62519304P 2004-11-05 2004-11-05
US66022605P 2005-03-10 2005-03-10
PCT/US2005/040068 WO2006065392A2 (en) 2004-11-05 2005-11-04 Cancer treatments

Publications (1)

Publication Number Publication Date
NO20072654L true NO20072654L (no) 2007-07-25

Family

ID=36588320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072654A NO20072654L (no) 2004-11-05 2007-05-24 Cancer behandling

Country Status (12)

Country Link
US (2) US20060128777A1 (no)
EP (1) EP1814544A4 (no)
JP (1) JP2008519047A (no)
CN (1) CN101933923A (no)
AR (1) AR054094A1 (no)
AU (1) AU2005317047A1 (no)
CA (1) CA2585659A1 (no)
CL (1) CL2009001721A1 (no)
MX (1) MX2007005361A (no)
NO (1) NO20072654L (no)
TW (1) TW200621240A (no)
WO (1) WO2006065392A2 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542445A (en) 2003-04-07 2008-03-28 Pharmacyclics Inc Hydroxamates as therapeutic agents
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US20090075967A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ceftriaxone
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2721722C (en) * 2008-04-17 2015-12-08 The Johns Hopkins University On01910.na enhances chemotherapeutic agent activity in drug-resistant tumors
MX2011002936A (es) * 2008-09-25 2011-04-11 Cephalon Inc Formulaciones liquidas de bendamustina.
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
UA102120C2 (ru) * 2008-12-03 2013-06-10 Астеллас Дойчленд Гмбх Пероральная форма дозирования бендамустина
NO2792369T3 (no) * 2009-02-25 2018-09-15
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
MX2011011109A (es) * 2009-04-28 2011-11-18 Cephalon Inc Formulaciones orales de bendamustina.
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
LT2528602T (lt) 2010-01-28 2017-02-27 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
PL2575784T3 (pl) 2010-06-02 2019-03-29 Astellas Deutschland Gmbh Doustne postaci dawkowania bendamustyny
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
PL2744515T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
ES2627820T3 (es) 2011-09-13 2017-07-31 Pharmacyclics, Inc. Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
HUE062230T2 (hu) 2012-03-20 2023-10-28 Eagle Pharmaceuticals Inc Bendamusztin folyékony készítmények bendamusztinra reagáló állapotok kezelési eljárásban történõ alkalmazásra, ahol a betegek csökkentett térfogatú bevitelre szorulnak
CA2867295C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US8927516B2 (en) * 2012-03-29 2015-01-06 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
US10220051B2 (en) 2012-03-29 2019-03-05 Institute For Cancer Research Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
EP3052655B1 (en) 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
CN115350155A (zh) * 2014-03-13 2022-11-18 V·沃道里斯 苯达莫司汀固体分散体和连续输液
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
AU688792B2 (en) * 1993-10-27 1998-03-19 Pharmacia & Upjohn Company Stabilized prostaglandin e1
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
GB9524334D0 (en) * 1995-11-28 1996-01-31 Philips Electronics Nv Mos transistor
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
NZ509376A (en) * 1998-07-09 2003-10-31 Francis A Nardella Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2002048141A1 (en) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
AU2002221115A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved absorbability
CN1568166A (zh) * 2001-10-15 2005-01-19 荷姆泰克股份有限公司 预防再狭窄的涂层支架
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
AU2003240391B8 (en) * 2002-05-09 2009-08-06 Hemoteq Ag Compounds and method for coating surfaces in a haemocompatible manner
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US6966329B2 (en) * 2003-01-27 2005-11-22 Hydraforce, Inc. Proportional pilot-operated flow control valve
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
US7157551B2 (en) * 2003-02-14 2007-01-02 Cephalon, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers

Also Published As

Publication number Publication date
CA2585659A1 (en) 2006-06-22
US20060128777A1 (en) 2006-06-15
TW200621240A (en) 2006-07-01
CN101933923A (zh) 2011-01-05
MX2007005361A (es) 2008-01-11
EP1814544A4 (en) 2009-12-02
AU2005317047A1 (en) 2006-06-22
WO2006065392A2 (en) 2006-06-22
AR054094A1 (es) 2007-06-06
US20090209606A1 (en) 2009-08-20
WO2006065392A8 (en) 2007-03-01
CL2009001721A1 (es) 2010-02-19
WO2006065392A3 (en) 2006-12-21
JP2008519047A (ja) 2008-06-05
EP1814544A2 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
NO20072654L (no) Cancer behandling
NO20070782L (no) Tetrapeptidanaloger.
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
ECSP056132A (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
NO20055731L (no) Cannabinoide reseptorligander og deres anvendelse
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
DK1761266T3 (da) Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
NO20013155L (no) Fremgangsmate ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
NO20060871L (no) Azepinderivater som farmasoytiske midler
ATE363896T1 (de) Gegen missbrauch gesicherte darreichungsform
DE602006007037D1 (de) Pyrrolotriazin-kinasehemmer
ATE499098T1 (de) Verwendung von parp-1-hemmern
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application